[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-346549-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-346549-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","dnmt3a-pr882c-driven-proliferation-and-anti-apoptotic-effects-in-pancreatic-cancer-cells","DNMT3A p.R882C driven proliferation and anti-apoptotic effects in pancreatic cancer cells","","Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with late diagnosis, rapid progression, and limited effective targeted therapies. Using formalin-fixed paraffin-embedded specimens from PDAC patients, whole-exome sequencing identified multiple high-risk deleterious variants, including the DNMT3A p.R882C mutation. Functional experiments in PANC-1 and PaTu 8988t cells showed that p.R882C does not change DNMT3A mRNA or protein levels, yet markedly increases proliferation and migration while suppressing apoptosis. These results support a critical role of DNMT3A p.R882C in PDAC pathogenesis and suggest potential therapeutic targeting.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/dnmt3a-pr882c-driven-proliferation-and-anti-apoptotic-effects-in-pancreatic-cancer-cells/346549/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/dnmt3a-pr882c-driven-proliferation-and-anti-apoptotic-effects-in-pancreatic-cancer-cells/346549.png","ImageObject",300,407,{"name":42,"@type":43},"Olivia Brown","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is DNMT3A p.R882C, and why is it important in PDAC?","Question",{"text":63,"@type":64},"DNMT3A p.R882C is a missense mutation identified as deleterious across multiple prediction algorithms. The study links it to PDAC progression by showing strong functional effects on cancer cell behavior.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Does DNMT3A p.R882C change DNMT3A expression levels?",{"text":68,"@type":64},"No. In the tested pancreatic cancer cell lines, the mutation did not significantly alter DNMT3A expression at either mRNA or protein levels.",{"name":70,"@type":61,"acceptedAnswer":71},"How does DNMT3A p.R882C influence pancreatic cancer cell survival and growth?",{"text":72,"@type":64},"It promotes proliferation and migration while inhibiting apoptosis. These combined effects suggest an anti-apoptotic and pro-tumor role in PDAC cells.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},346549,1790214179,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nDNMT3A p.R882C driven proliferation and anti-apoptotic effects in pancreatic cancer cells  \nZhen Qu1,2, Jinglin Mao2, Yang Qian2, Jingyu Cao1 & Shulong Jiang3􀀍  \nPancreatic cancer, one of the most lethal malignancies, is characterized by insidious onset, frequent late-stage diagnosis, rapid progression, and limited surgical opportunities. Pancreatic ductaladenocarcinoma (PDAC), accounting for over 90% of pancreatic cancer cases, remains a therapeutic challenge due to the scarcity of effective targeted therapies. In this study, we collected formalin-fixed paraffin-embedded (FFPE) specimens from three patients with moderately to poorly differentiated PDAC, extracted genomic DNA, and performed whole-exome sequencing. Through bioinformatics analysis, we identified 68 high-risk deleterious variants, including the DNMT3A p.R882C mutation.  \nThis mutation exhibits low frequency in public databases (e.g., esp6500si, GnomAD) and is consistently predicted as deleterious by multiple algorithms (SIFT, Polyphen, LRT, CADD). To investigate its functional impact, wild-type and mutant DNMT3A constructs were cloned into p3xflag-CMV-10 plasmids and transfected into the pancreatic cancer cell lines PANC-1 and PaTu 8988t. In vitro cellular experiments demonstrated that the DNMT3A p.R882C mutation does not alter DNMT3A expression at mRNA or protein levels but significantly promotes cancer cell proliferation and migration while inhibiting apoptosis. These findings suggest that the DNMT3A p.R882C mutation may play a critical role in PDAC pathogenesis. This study not only provides essential laboratory evidence for elucidating PDAC development but also offers new insights for potential targeted therapeutic strategies in pancreatic cancer.  \nKeywords PDAC, DNMT3A, Mutation, Whole-exome sequencing  \nPancreatic cancer remains one of the most lethal malignancies worldwide, with pancreatic ductaladenocarcinoma (PDAC) constituting over 90% of pancreatic cancer cases and demonstrating a 5-year survival rate below 13%1. Characterized by late diagnosis, aggressive progression, and profound therapeutic resistance, PDAC is projected to become the second-leading cause of cancer-related deaths by 20302. This dismal prognosis underscores the urgent need to decipher PDAC’s complex molecular landscape and develop precision therapeutic strategies.  \nThe genomic landscape of PDAC is dominated by four hallmark driver genes: KRAS (94.7%), TP53 (81.5%), CDKN2A (25.2%), and SMAD4 (33.8%)3. KRAS mutations initiate tumorigenesis by constitutively activating MAPK and PI3K-AKT pathways, while later TP53 loss enables genomic instability and metastatic dissemination4. The CDKN2A gene encodes two proteins, p16INK4a and p14ARF. p16INK4a inhibits CDK4 activity, is a regulator of cell cycle progression, and a tumor suppressor gene5. As for SMAD4, it plays a role in activating transforming growth factor-β (TGF-β) signaling pathway and translocating to the nucleus as a transcriptional cofactor to facilitate the transcription of TGF-β-responsive genes in cancer cells, thereby regulating a variety of critical processes, including tumor development and immunotherapy6. Furthermore, emerging evidence highlights the role of epigenetic dysregulation, particularly enhancer reprogramming mediated by FOXA1 and super-enhancer complexes, in maintaining oncogenic transcriptional programs7. Although numerous studies have been conducted on the driver genes of pancreatic cancer, the development of targeted therapies for PDAChas still seen limited progress8.  \nDNA (cytosine-5)-methyltransferase 3 A (DNMT3A) is involved inde novo establishment of DNA methylation and plays a vital role in tumorigenesis9, 10. Missense mutations in the DNMT3A gene occur frequently at the early stages of tumor development and are often observed in hematologic malignances, especially in acute myeloid leukemia (AML), with a prevalence of the p.R8","cbCaiqtOM3i4bk8r","https://ap.wps.com/l/cbCaiqtOM3i4bk8r","pdf",3685612,11,"English","# Background\n## Challenges in PDAC treatment and prognosis\n## Driver genes and molecular drivers in PDAC\n## Epigenetic dysregulation and DNMT3A relevance\n# Study design and methods\n## Whole-exome sequencing of FFPE patient specimens\n## Variant prediction and selection\n## DNMT3A cloning and cell line transfection\n# Findings\n## DNMT3A p.R882C effects on expression\n## Proliferation and migration promotion\n## Apoptosis inhibition","[{\"question\":\"What is DNMT3A p.R882C, and why is it important in PDAC?\",\"answer\":\"DNMT3A p.R882C is a missense mutation identified as deleterious across multiple prediction algorithms. The study links it to PDAC progression by showing strong functional effects on cancer cell behavior.\"},{\"question\":\"Does DNMT3A p.R882C change DNMT3A expression levels?\",\"answer\":\"No. In the tested pancreatic cancer cell lines, the mutation did not significantly alter DNMT3A expression at either mRNA or protein levels.\"},{\"question\":\"How does DNMT3A p.R882C influence pancreatic cancer cell survival and growth?\",\"answer\":\"It promotes proliferation and migration while inhibiting apoptosis. These combined effects suggest an anti-apoptotic and pro-tumor role in PDAC cells.\"}]","DNMT3A p.R882C driven proliferation and anti-apoptotic effects in pancreatic cancer cells | PDF",1790061945,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9829452363bbac39a81f15f4b486447c.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7c37c85b248a38da6d91a96a33331688.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4f0a4e56d33478b6cc1e7e3b57aeb055.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a9b62deb7a5691028247f33799c0b0a0.webp",980,1287]